



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification n<sup>4</sup> :</b> G01N 33/574, 33/92, 33/577 C12Q 1/00 // C12Q 1/32	<b>A1</b>	<b>(11) International Publication Number:</b> WO 90/11526 <b>(43) International Publication Date:</b> 4 October 1990 (04.10.90)
<b>(21) International Application Number:</b> PCT/GB89/00294 <b>(22) International Filing Date:</b> 20 March 1989 (20.03.89)  <b>(71) Applicant (for all designated States except US):</b> ENZYMATIX, LTD. [GB/GB]; Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only) :</b> EVANS, Christopher, Thomas [GB/GB]; Enzymatix Ltd., Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). <b>(74) Agent:</b> GILL JENNINGS & EVERY; 53/64 Chancery Lane, London WC2A 1HN (GB).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CH (European patent), DE, DE (European patent), FR (European patent), GB, GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.		<b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> CANCER DIAGNOSIS  <b>(57) Abstract</b>  A diagnostic kit, for determining the ratio of lithocholic acid (LA) to deoxycholic acid (DA) in, say, a faecal sample, comprises a substrate for one acid; a substrate for the other or both acids; an agent which reacts with each substrate to produce a detectable response proportional to the presence of the acid-labelled substrate complex, the relative responses being different in the cases when the LA:DA ratio is normal and substantially higher than normal, respectively.		

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LJ	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

-1-

## CANCER DIAGNOSIS

Field of the Invention

This invention relates to a kit for use in a rapid diagnostic process for determining the ratio of lithocholic acid (LA) and deoxycholic acid (DA) in a faecal extract; these two bile acids have been implicated in human colo-rectal carcinogenesis. This invention has direct application in the preliminary screening of faeces from high risk groups (aged between 35-60) for predicting the likelihood of developing colo-rectal cancer.

Background of the Invention

Large bowel carcinogenesis is a multi-stage process involving the formation and then growth of an adenoma, the development of increasingly severe epithelial dysplasia, and finally the progression to malignancy. There is a substantial amount of evidence incriminating bile acids in colo-rectal carcinogenesis, and the total faecal bile acid concentration is highly correlated with the incidence of large bowel cancer in population studies. However, the correlation is poor in most case-control studies, suggesting that the relationship is more complex. Recent studies suggest that a better discriminant is the ratio of the two principal faecal bile acids, LA and DA; the evidence comes from in vitro experiments and from studies of high risk cancer patients and of animals.

Marisawa et al, JNCI 53, 1093-1097 (1974), report animal studies showing that the secondary bile acids (LA and DA) were co-carcinogenic in the rat colon, whereas the primary bile acids (cholic and chenodeoxycholic acids) were not.

Owen et al, Eur. J. Cancer Clin. Oncol. 19, 1307 (1983), show that a high LA:DA ratio or a very low LA:DA ratio is comutagenic, but more equal mixtures are less

-2-

so. Further, the LA:DA ratio increases with adenoma size, i.e. as the malignant potential of the adenoma increases.

Wilpart et al, Gastroenterol. Clin. Biol. 8, 337-342  
5 (1984), used animal experiments to show that increased dietary fat causes a change in the LA:DA ratio, to one which is more comutagenic. Thompson et al, Biochem Soc. Trans. 13 392 (1985), report a similar result in a study of human volunteers on a high-fat diet, and the converse  
10 when volunteers were put on a high-fibre diet.

Apart from the effect on dietary fat and fibre, little is known of the factors determining the LA:DA ratio. LA and DA are the products of 7 $\alpha$ -dehydroxylation of chenodeoxycholic and cholic acids. Synthesis of  
15 chenodeoxycholic acid is reportedly from dietary cholesterol. Thus, the ratio could be a measure of the response to dietary cholesterol; this would support the epidemiological observations of Lui et al, Lancet 2, 784-789 (1979).

20 Owen et al, supra, conclude that the LA:DA ratio "may be an important aetiological factor in colo-rectal cancer". Further work by Owen et al presents evidence "that the ratio of the two major faecal bile acids, lithocholic and deoxycholic acids, may be a good risk  
25 marker"; see Nutrition and Cancer 9 Nos. 2&3, 67-71 (1987). However, the evidence is not conclusive.

It is an object of this invention to provide a rapid and cost efficient methodology to facilitate screening of faecal samples for measurement of the LA:DA ratio as an  
30 indication of the potential to contract colo-rectal cancer.

#### Summary of the Invention

A novel, rapid method for measuring the ratio of lithocholic acid to deoxycholic acid in a sample is based  
35 on the use of substrates to LA and DA, respectively. A

-3-

novel kit comprises these substrates and an agent which reacts with each substrate to produce a detectable response proportional to the presence of the acid-labelled substrate complex, the relative responses being  
5 different in the cases when the LA:DA ratio is normal and substantially higher than normal, respectively.

The value of such a kit has been established by recent, incontrovertible evidence that the LA:DA ratio is a distinctive marker for colo-rectal cancer, including  
10 tumours of Duke's grades A, B, C1 and C2, tumours of the caecum and ascending colon, sigmoid and recto-sigmoid colon, and rectum, by comparison with controls, in a study of 78 subjects. Other studies have been confirmatory.

15 Description of the Invention

The term "substrate" is used herein to describe a material with which LA or DA reacts or binds, i.e. a reacting or binding partner, preferably specifically in context. The material may be, for example, an enzyme for  
20 which LA or DA is, in the more usual sense, a substrate.

The substrates may each be specific for one of the two acids. The substrates are, for example, monoclonal or polyclonal antibodies to LA and DA, respectively.

Desired monoclonal antibodies can be prepared in  
25 conventional manner. Ultra-pure samples of LA and DA are used as antigens and administered to mice, to obtain antibodies using standard techniques well known to those versed in the art of preparing antibodies. The monoclonal antibodies are recovered, purified and tested  
30 for their cross-reactivity with all other bile acids. Monoclonals showing absolute specificity for LA and DA respectively are collected and used in the novel kit.

Desired polyclonal antibodies can also be prepared in conventional manner. The antigens, LA and DA, are  
35 injected into sheep, rabbit or donkey as classical routes

-4-

to obtaining polyclonal antibodies. The antigens themselves are normally bound in different ways to a larger carrier molecule, one which is relatively inert. Albumin is used frequently. The antigens are bound in  
5 such a way so as to expose only specific sites for targets for the antibodies. The bile acids usually only differ in the number and position of hydroxyl groups, e.g. 7 $\alpha$ -hydroxyl, 3 $\alpha$ -, 12 $\alpha$ - etc.

The molecules can be arranged and bound to expose  
10 the hydroxyl groups in the 3 $\alpha$  and 12 $\alpha$  positions or 3 $\alpha$  and 7 $\alpha$  positions. In this way the immunisation process can lead to the production of very specific polyclonal antibody preparations.

The sheep or other animal is bled after 6-9 months  
15 and the best individual animal maintained once the antibodies showing the desired characteristics have been selected. The antibodies are recovered by standard methods of filtration, centrifugation, ammonium sulphate precipitation and chromatographic absorption techniques  
20 etc.

The antibodies are purified and tagged with enzymes such as horseradish peroxides or alkaline phosphatase as used in standard ELISA procedures.

The antisera are evaluated for their cross-  
25 reactivity against 20-30 related compounds, especially bile acid derivatives. The affinity constants, titre etc. are determined for the individual polyclonal antibodies.

Assay systems are then constructed, setting up  
30 competitive and non-competitive methods evaluating reaction time, sensitivity, component stability, kit stability, recovery, precision, matrix, etc.

The antibodies are added to a faecal extract or other suitable sample, and bind specifically to either  
35 lithocholate or deoxycholate. After washing, the

-5-

LA/DA-bound conjugates are monitored to determine the concentration of the label and thus of LA and of DA. The method is direct and specific for measuring the LA:DA ratio.

5       The label is, for example, an enzyme or a fluorescent, luminescent, radioactive or ferro-magnetic compound. The most suitable fluorescent probe is fluorescein. In fluorescence polarisation, a labelled sample is excited with polarised light and the degree of  
10       polarisation of the emitted light is measured; as antigen binds to the antibody, its rotation slows down and the degree of polarisation increases.

          For use in a chemiluminescent, e.g. bioluminescent, assay, light emitted by the bound, labelled antibody is  
15       measured. A catalytic protein or enzyme such as luciferase increases the efficiency of the luminescent reaction.

          For economy and simplicity, enzyme-linked immunoassays are preferred. The enzyme label is, for  
20       example, alkaline phosphatase, glucose oxidase, galactosidase, peroxidase, urease or luciferase. In an enzyme-linked immunosorbent assay, the amount of bound, labelled antibody is determined by recording the light emitted when the enzyme reacts with its substrate to form  
25       a chromagen.

          In order to determine the respective amount of LA and DA in a given sample, some means for recording a signal associated with the label, e.g. a colorimeter, is used. The sample may be contacted simultaneously with  
30       the two polyclonal antibodies, each having a different label generating a distinct signal which can be recorded. Alternatively, a sample may be contacted with the labelled antibodies sequentially, or the sample may be divided and parts contacted with the antibodies  
35       separately and simultaneously.

-6-

The substrates themselves may be enzymes. For example, they may be respectively substrates for 3 $\alpha$ -hydroxy bile acids (including LA and DA) and 12 $\alpha$ -hydroxy bile acids (DA but not LA).

5        More specifically, a kit of the invention may be based on a simple colorimetric method for measuring the specific LA:DA ratio in faeces using an enzymatic technique. The two bile acids are distinguished from the faecal pool of bile acids by using differential assays  
10 composed of alpha-hydroxysteroid dehydrogenase ( $\alpha$ -HSDH). A sample is assayed for the concentration of 3 $\alpha$ -hydroxy bile acids and 12 $\alpha$ -hydroxy bile acids using the 3 $\alpha$ -HSDH and 12 $\alpha$ -HSDH enzyme respectively. The  $\alpha$ -HSDH reactions are coupled, via the NADH coproduct, through a second  
15 enzyme, diaphorase, which reduces a chromogenic substrate to generate a coloured compound. The increase in absorbance due to this chromagen is directly proportional to the concentration of bile acid present. The difference in absorbance readings between 3 $\alpha$ -HSDH and  
20 12 $\alpha$ -HSDH reactions is directly proportional to the LA concentration in the faecal sample: the 12 $\alpha$ -HSDH reaction quantitates the DA content of the sample.

The specific alpha-hydroxysteroid dehydrogenases (3 $\alpha$ -, 7 $\alpha$ -, 12 $\alpha$ -HSDH's) convert bile acid substrates  
25 containing 3 $\alpha$ -, 7 $\alpha$ -, 12 $\alpha$ -hydroxyl groups to the corresponding keto acids and generate reduced cofactor (NADH) concomitantly. The keto products or, preferably, the reduced cofactor product can be measured using chromogenic techniques. For example, the present  
30 invention utilises the coupling of a diaphorase-mediated chromogenic system, such as nitrotetrazolium salt, to the products of the  $\alpha$ -HSDH reaction.

Means may be provided, for quantitatively assaying the bile acid substrates using buffered reaction mixtures  
35 containing  $\alpha$ -HSDH enzyme, NAD<sup>+</sup>, diaphorase and oxidised



-7-

chromagen, and following the increase in absorbance spectrophotometrically.

The present invention provides a means of indirectly determining the level of LA by differential assays using  
5  $\alpha$ -HSDH's, for which there is no known direct enzyme assay.

A kit of the invention may comprise the respective substrates immobilised on the same or different supports; the sample is then brought into contact with the  
10 support(s). Depending on the nature of the label, the support may then be washed and the signal proportional to bound LA or DA recorded following generation of the appropriate signal by contact with a substrate for the label.

15 A kit of the invention comprises the two substrates, preferably together with an enzyme substrate or other material which can be used to generate a signal associated with the, say, labelled antibody-bile acid reaction product. Means for observing and recording the  
20 signal are preferably also provided. The means may discriminate samples from patients which are most at risk, e.g. those in which the LA:DA ratio is unacceptably high, e.g. above 0.8 or 0.9. Risk patients may exhibit a ratio of 0.8 to 1.1, patients already exhibiting cancer a  
25 ratio of 1.3 to 4.0.

The sample which is observed may be from faeces, bile juice, urine or blood. Urine may be a marker for colo-rectal bile acid overflow.

There are various ways in which the present  
30 invention may be used in practice. For example, the kit may be used for mass screenings. The reactions could be conducted in a microtitre dish (having, say, 500 wells), and the absorbance of washed and reacted labelled antibodies monitored by a large autoscanner. The samples  
35 could be treated in duplicate with the same (or

-8-

different) chromogenic substrate. The direct ratio of absorbances can be measured. This procedure enables hundreds of samples per day to be screened.

Alternatively, the kit may be used in the form of a simple device for use in a doctor's or nurse's surgery. A patient's faecal sample would have to be extracted. A, say, 1 ml eluate sample can then be split and reacted with the two antibodies separately and their absorbances monitored in a hand-held colorimeter. This could give a result within 30-60 min, allowing immediate doctor/patient discussions.

Further, the novel kit can be used as an OTC aid. An individual could buy a faecal bowel cancer test kit comprising 2 dipsticks coated in labelled antibodies and marked A and B. Each dipstick would be immersed into a fresh faecal sample (on toilet paper) then pushed into a compartmented tube (to wash and react the dipstick). The test would be qualitative, but any major colour difference between the 2 dipsticks would indicate a high ratio effect and the possible need for referral to a doctor.

In either case, the kit of the invention can be used as part of an assay for cancer utilising the substrates etc, and associated with a method of treatment by administering, to a subject having an increased LA:DA ratio, a suitable medicament or dietary regime adapted to reduce the ratio.

The following Example illustrates the invention.

Example

For assay purposes, a kit comprises containers containing given amounts of the reactants used in the following procedure:

A sample of faecal extract is dissolved in a suitable reconstituting buffer (e.g. 50 mM phosphate, Tris, glycine-NaOH) pH 6-9, preferably pH 8. An aliquot

-9-

of the sample (e.g. 100 ml) is then mixed with a reaction mixture containing nicotinamide adeninedinucleotide (NAD<sup>+</sup>), phosphate buffer, nitrotetrazolium blue (or other chromogen), Titron x-100, diaphorase (Clostridium sp. or pig heart enzyme) and 3 $\alpha$ -HSDH (from Pseudomonas sp. or another source). The mixture is incubated at 37°C for 15 min. The reaction is stopped using a suitable stopper reagent (e.g. 0.5% sodium dodecylsulphate). During the reaction, the 3 $\alpha$ -hydroxyl groups on the bile acids present in the sample will be oxidised to the corresponding keto acids by the 3 $\alpha$ -HSDH enzyme. Concomitantly, the NAD<sup>+</sup> present is reduced to NADH. The NADH reducing equivalents are then transferred to the chromogenic substrate present by action of the enzyme diaphorase. A typical chromogenic salt (nitrotetrazolium blue) generates a stable blue formazon derivative on the end product. The amount of formazon produced is measured photometrically at 540 nm. The net absorbance obtained (i.e. the difference between the absorbances of the sample and a blank) is directly proportional to the concentration of 3 $\alpha$ -hydroxy bile acid present in the sample.

The faecal sample is reacted for a second time, in the same reaction mixture as that described above, except that it contains the enzyme 12 $\alpha$ -hydroxysteroid dehydrogenase (12 $\alpha$ -HSDH) instead of the 3 $\alpha$ -HSDH. After incubation for 15 min at 37°C, the net absorbance obtained from the production of the blue formazon derivative is proportional to the concentration of 12 $\alpha$ -hydroxy bile acids present in the sample.

The determination of the LA concentration in the faecal extract is made by subtracting the 12 $\alpha$  test result from the 3 $\alpha$  test result. The difference is directly correlated with the concentration of LA in the extract as this bile acid contributes to over 98% of the remaining

-10-

3 $\alpha$ -hydroxy content of faecal bile acid once the  
12 $\alpha$ -hydroxy bile acids have been assayed.

If desired, the faecal extract can be reacted for a  
third time, under identical conditions to those described  
5 above, except that the mixture contains a specific  
enzyme, 7 $\alpha$ -hydroxysteroid dehydrogenase (7 $\alpha$ -HSDH),  
instead of the 3 $\alpha$ - or 12 $\alpha$ -HSDH enzyme. After incubation  
for 15 min at 37°C, the net absorbance obtained from the  
production of blue formazon (or other chromogenic  
10 product) is proportional to the concentration of  
7 $\alpha$ -hydroxy bile acid present. This provides a check on  
the LA concentration, giving the maximum percentage error  
in the LA determination by measuring the cholate and  
chenodeoxycholate present. It is well known that the  
15 concentration of LA and DA in bile fluid is very low or  
zero whilst, in faecal extracts, the levels of cholate  
and chenodeoxycholate are very low. Therefore, it is  
preferred to use only the first two assays.

20

25

30

35

-11-


CLAIMS

1. A diagnostic kit, for determining the ratio of lithocholic acid (LA) to deoxycholic acid (DA) in, say, a faecal sample, comprising a substrate for one acid; a  
5 substrate for the other or both acids; an agent which reacts with each substrate to produce a detectable response proportional to the presence of the acid-labelled substrate complex, the relative responses being different in the cases when the LA:DA ratio is normal and  
10 substantially higher than normal, respectively.
2. A kit according to claim 1, wherein each substrate is a labelled monoclonal antibody for the respective acid.
3. A kit according to claim 1, wherein each substrate  
15 is a labelled polyclonal antibody for the respective acid.
4. A kit according to claim 1, wherein the substrates are respectively for 3 $\alpha$ -hydroxy bile acids and 12 $\alpha$ -hydroxy bile acids.
- 20 5. A kit according to claim 4, wherein the substrates are enzymes.
6. A kit according to claim 5, wherein the enzymes are labelled.
7. A kit according to any of claims 2, 3 and 6, wherein  
25 the label is luminescent or chromogenic.
8. A kit according to claim 5, wherein the agent comprises reactants which generate a coloured species when coupled to the respective enzyme-substrate reactions.
- 30 9. A kit according to any preceding claim, which comprises means for determining the LA:DA ratio and displaying the different responses.

35

# INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 89/00294

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>4</sup> : G 01 N 33/574, 33/92, 33/577, C 12 Q 1/00, //C 12 Q 1/32						
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">IPC<sup>4</sup></td> <td style="padding: 5px;">G 01 N, C 12 Q</td> </tr> </table> <div style="border-top: 1px solid black; padding-top: 5px; margin-top: 5px;">           Documentation Searched other than Minimum Documentation            to the Extent that such Documents are Included in the Fields Searched *         </div>			Classification System	Classification Symbols	IPC <sup>4</sup>	G 01 N, C 12 Q
Classification System	Classification Symbols					
IPC <sup>4</sup>	G 01 N, C 12 Q					
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> *						
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>				
X	EP, A, 0037742 (NYEGAARD & CO. A/S) 14 October 1981, see abstract; page 2, line 24 - page 3, line 37	1				
Y	--	4, 5, 8				
Y	Chemical Abstracts, vol. 106, no. 25, 22 June 1987 (Columbus, Ohio, US) see page 349, abstract no. 210560r & JP, A, 61260896 (SEKISUI CHEMICAL CO. LTD) 19 November 1986	4, 5, 8				
Y	Biochem. Soc. Trans., vol. 12, 1984, 607th Meeting, London (GB) R.W. Owen et al.: "The faecal ratio of lithocholic acid to deoxycholic acid may be an important aetiological factor in colo-rectal cancer", page 861, see page 861	1, 3				
Y	Chemical Abstracts, vol. 92, no. 5, 4 February 1980 (Columbus, Ohio, US)	1, 3				
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>						
<b>IV. CERTIFICATION</b>						
Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold;">26th June 1989</div>		Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold;">20. 07. 89</div>				
International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div>		Signature of Authorized Officer <div style="text-align: center;">   <b>P.C.G. VAN DER PUTTEN</b> </div>				

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
	O.A. Janne et al.: "Radioimmunoassay of primary and secondary bile acids in serum with specific antisera and iodine 125-labeled ligands", see page 376, abstract no. 37184p & Radioimmunoassay Relat. Proced. Med. Proc. Int. Symp. 1977 (Pub. 1978) 2, 285-93	
	--	
Y	Nutrition & Cancer, vol. 9, nos. 2,3; 1987 Lawrence Erlbaum Ass. Inc. R.W. Owen et al.: "The importance of the ratio of lithocholic to deoxycholic acid in large bowel carcinogenesis", pages 67-71, see pages 67-70 (cited in the application)	1,4,5,8
	--	
Y	Clinical Chemistry, vol. 26, no. 9, August 1980, Winston-Salem (US) M.J. Crowell et al.: "Enzymic determination of 3 $\alpha$ -, 7 $\alpha$ -, and 12 $\alpha$ -hydroxyl groups of fecal bile salts", pages 1298-1300, see the whole article	1,4,5,8
	--	
A	Gastroenterol. Clin. Biol., vol. 8, 1984, P. Masson, Paris (FR) M. Wilpart et al.: "Lipides alimentaires et variations du débit fécal et des composants métaboliques des selles chez le rat", pages 337-342, see the abstract; page 338, column 2, lines 32-36; page 341, column 2, lines 1-13 (cited in the application)	1
	-----	

GB 8900294  
SA 27765

**This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 11/07/89. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0037742	14-10-81	AT-T- E10860	15-01-85
		CA-A- 1163907	20-03-84
		JP-A- 56151499	24-11-81
<hr/>			

**FORM P0679**

**Et** For more details about this annex : see Official Journal of the European Patent Office, No. 12/82